Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer.
Kingston B, Pearson A, Herrera-Abreu MT, Sim LX, Cutts RJ, Shah H, Moretti L, Kilburn LS, Johnson H, Macpherson IR, Ring A, Bliss JM, Hou Y, Toy W, Katzenellenbogen JA, Chandarlapaty S, Turner NC. Kingston B, et al. Among authors: bliss jm. Cancer Discov. 2024 Feb 8;14(2):274-289. doi: 10.1158/2159-8290.CD-22-1387. Cancer Discov. 2024. PMID: 37982575 Free PMC article.
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Coombes RC, et al. Among authors: bliss jm. J Clin Oncol. 2011 Aug 20;29(24):3247-54. doi: 10.1200/JCO.2010.32.7254. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768453 Clinical Trial.
Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase?
Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, Johnson L, Kilburn LS, Makris A, Mansi J, Reed M, Ring A, Robinson A, Simmonds P, Thomas G, Bliss JM. Leonard R, et al. Among authors: bliss jm. Br J Cancer. 2011 Oct 25;105(9):1260-6. doi: 10.1038/bjc.2011.377. Epub 2011 Oct 11. Br J Cancer. 2011. PMID: 21989185 Free PMC article.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Johnston SR, et al. Among authors: bliss jm. Lancet Oncol. 2013 Sep;14(10):989-98. doi: 10.1016/S1470-2045(13)70322-X. Epub 2013 Jul 29. Lancet Oncol. 2013. PMID: 23902874 Free article. Clinical Trial.
Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM. Coombes RC, et al. Among authors: bliss jm. Eur J Cancer. 2016 Jun;60:146-53. doi: 10.1016/j.ejca.2016.03.001. Epub 2016 Apr 26. Eur J Cancer. 2016. PMID: 27125966 Clinical Trial.
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC. Fribbens C, et al. Among authors: bliss jm. J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269946 Clinical Trial.
256 results